medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2011, Number 1

<< Back Next >>

Rev Esp Med Quir 2011; 16 (1)

Therapeutic goals in the metabolic control of patients with diabetes mellitus 2 assisting to the internal medicine external consultation service of the Regional Hospital 1° de Octubre

Conrado AS, Calderón ER, Mello GM, Rosas BJV

Language: Spanish
References: 32
Page: 18-26
PDF size: 87.14 Kb.


ABSTRACT

Background: Diabetes mellitus is a public health problem worldwide for its high incidence and prevalence, its chronic complications, with great economic impact which explains the importance of all tasks to achieve adequate glycemic control.
Objective: To identify the components of metabolic control treated in the outpatients department of internal medicine under the ADA and NOM criteria after two visits at Hospital Regional 1° de Octubre.
Material and methods: We performed a retrospective, analytical, cross-sectional study with 100 cases of patients with diabetes mellitus type 2 attended from 2008 to 2009 that had at least two appointments.
Results: Of the 100 cases studied 75% were women, with a mean age of 58.18 ± 12.12, evolution of disease 13.14 ± 10.28 years, more than a third of comorbidities associated with hypertension, mainly high blood pressure (73%) and obesity (55%), in all biochemical determinations were better in the second visit, yet only one patient fulfilled all the goals according to the ADA and none according to the NOM.
Conclusions: We could not document control of diabetic patients in the files evaluated, interdisciplinary management is required to achieve the goals.


REFERENCES

  1. Archivos de estadística del Hospital Regional 1° de Octubre, ISSSTE.

  2. Norma Oficial Mexicana (NOM-015-SSA2-1994): “Para la prevención, tratamiento y control de la diabetes mellitus en la atención primaria”.

  3. Shichiri M. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(2):B21-B29.

  4. Hirsch IB, Farkas-Hirsh R, Skyler JS. Intensive insulin therapy for treatment of type I diabetes. Diabetes Care 1990;13:1265-1283.

  5. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039.

  6. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 1999;16:716-730.

  7. Brener BM, Cooper ME, De Zeeuw D, Keane WF, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.

  8. Ríos JM, Rull JA. El síndrome clínico de diabetes mellitus. En: Rull J, Zorrilla E, Jadzinsky M, Santiago JV, editores. Diabetes mellitus, complicaciones crónicas. Cd. de México: Nueva Editorial Interamericana; 1992:3-16.

  9. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-1940.

  10. World Health Organization. International statistical classification of diseases and related health problems. Tenth Revision (vol. 1), Ginebra WHO, 1992.

  11. American Diabetes Association. Therapy for diabetes mellitus and related disorders. ADA Clinical Education Program 1991:92-99.

  12. Secretaría de Salud. Causas de mortalidad en México 2000. Estadísticas de mortalidad. Disponible en: http//www.ssa.gob.mx.

  13. American College of Endocrinology. Consensus status on guidelines for glycemic control. Endocrine Practice 2008;8(Suppl 1):5-11.

  14. Gómez-Pérez FJ. Diabetes sacarina. In: Jinich H, Woolrich J, Olivares L, Chávez I, editores. Tratado de medicina interna. Academia Nacional de Medicina: El Manual Moderno; 1988:78-218.

  15. American Diabetes Association. Clinical practice recommendations 2009. Diabetes Care 2009;23(Suppl 1):S1-S116.

  16. Diabetes Control and Complications Research Group. Diabetes Control and Complications Trial (DCCT) update. Diabetes Care 1994;13:427-433.

  17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

  18. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes Steno 2. N Engl J Med 2003;348:383-393.

  19. Terrés-Speziale A. Evaluación de tres estudios internacionales multicéntricos prospectivos en el estudio y manejo de la diabetes mellitus. Rev Mex Patol Clin 2006;53:104-113.

  20. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 1998;21(Suppl 1):S20-S22.

  21. Puder JJ, Endras J, Moriconi N, Keller U. How patients with insulin treated type 1 and type 2 diabetes view their own and their physician’s treatment goals. Swiss Med Wkly 2006;136:574-580.

  22. Almendárez P, Meaney A, Vela A, Rivera J, et al. Alcance de metas cardiometabólicas en pacientes de alto riesgo en un hospital de tercer nivel. Rev Mex Cardiol 2009;20:109-115.

  23. Carranza MJ, Escutia VY. Abordaje fisiopatogénico intensivo de pacientes con diabetes en un hospital general. Med Int Mex 2009;25(1):3-8.

  24. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010;(Suppl 1):S11-S61.

  25. Skinner T. Psychological barriers. Eur J Endocrinol 2004;151:T13-T17.

  26. Butler C, Peters J, Stott N. Glycated haemoglobin and metabolic control of diabetes mellitus: external versus locally established clinical targets for primary care. BMJ 1995;310:784-788.

  27. Huang E, Gorawara-Bhat R, Chin M. Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 2005;53:306-311.

  28. Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol 2004;151(Suppl 2):T3-T7.

  29. Heisler M, Vijan S, Anderson R, Ubel P, et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? J Gen Intern Med 2003;18:893-902.

  30. Crivera C, Suh D, Huang E, Cagliero E, et al. The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients. Curr Med Res Opin 2006;22:2301-2311.

  31. Clarke P, Gray A, Adler A, Stevens R, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS 51). Diabetologia 2001;44(3):298-304.

  32. Genuth SM. The role of the National Diabetes Advisory Board in diabetes management. Diabetes Care 1998;17(1):28-31.




2020     |     www.medigraphic.com